Sugi Predict

Sugi Predict / Compounds / SCHEMBL393713

SCHEMBL393713

SCHEMBL393713

COC(=O)C1COC(C)(C)O1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CA2 P00918 5/20 0.35
▸ HCRTR2 O43614 3/20 0.34
▸ HCRTR1 O43613 2/20 0.34
▸ MMP2 P08253 1/20 0.33
▸ ANPEP P15144 1/20 0.33
▸ CA1 P00915 2/20 0.32
▸ PDK1 Q15118 1/20 0.32
▸ PPM1B O75688 1/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ PPP1CC P36873 1/20 0.32
▸ MIF P14174 2/20 0.31
▸ MAPT P10636 2/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ ITGA4 P13612 1/20 0.31
▸ GAA P10253 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL877770 1.00 L3MBTL1 (0.35) L3MBTL1CA2HCRTR2HCRTR1MMP2
SCHEMBL1487144 1.00 L3MBTL1 (0.35) L3MBTL1CA2HCRTR2HCRTR1MMP2
SCHEMBL15471264 0.82 CA2 (0.34) CA2HCRTR2HCRTR1ALDH1A1
SCHEMBL2934643 0.81 MMP2 (0.34) CA2MMP2ANPEPPDK1PPM1B
SCHEMBL15345969 0.81 MMP2 (0.34) CA2MMP2ANPEPPDK1PPM1B
SCHEMBL13085057 0.79 LMNA (0.40) CA2PPM1BPTPN1PPP1CCALDH1A1
SCHEMBL17904756 0.79 LMNA (0.40) CA2PPM1BPTPN1PPP1CCALDH1A1
SCHEMBL10716759 0.79 ALDH1A1 (0.39) L3MBTL1CA2HCRTR2HCRTR1CA1
SCHEMBL3020689 0.79 CA2 (0.35) L3MBTL1CA2HCRTR2HCRTR1CA1
SCHEMBL883211 0.79 CA2 (0.35) L3MBTL1CA2HCRTR2HCRTR1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001060986-A9 ESTERASE ENZYMES HAVING SELECTIVE ACTIVITY THERMOGEN INC (US) 2002-10-17 — — WO claimed
WO-2001060986-A2 ESTERASE ENZYMES HAVING SELECTIVE ACTIVITY THERMOGEN, INC. (US) 2001-08-23 — — WO claimed
US-4735959-A HYPOGLYCEMIC AGENTS DR. KARL THOMAE GMBH (DE) 1988-04-05 — — US claimed
US-4575558-A Preparation of optically active 1,3-dioxolane-4-methanol compounds AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1986-03-11 — — US claimed
EP-4729059-A2 THIAZOLO [5,4-B] PYRIDINE MALT-1 INHIBITORS Abbvie Inc. (US) 2026-04-22 — — EP disclosed
US-20250084099-A1 THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS ABBVIE INC (US) 2025-03-13 — — US disclosed
WO-2025026270-A1 BENZO NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2025-02-06 — — WO disclosed
EP-4499650-A1 THIAZOLO [5,4-B] PYRIDINE MALT-1 INHIBITORS Abbvie Inc. (US) 2025-02-05 — — EP disclosed
US-20240182463-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG SHIONOGI & CO., LTD. (JP) 2024-06-06 — — US disclosed
US-11993613-B2 Thiazolo[5,4-b]pyridine MALT-1 inhibitors ABBVIE INC. (US) 2024-05-28 — — US disclosed
CN-110741087-B Targeting composition 阿布特斯生物制药公司 2024-05-14 — — CN disclosed
CN-110267944-B Compounds useful for the treatment of gastrointestinal disorders 阿德利克斯股份有限公司 2024-03-08 — — CN disclosed
US-4735959-A HYPOGLYCEMIC AGENTS DR. KARL THOMAE GMBH (DE) 1988-04-05 — — US disclosed
EP-0210589-A2 Process for preparing optically active alpha-halogen ketals ZAMBON S.p.A. (IT) 1987-02-04 — — EP disclosed
EP-0173714-A4 PREPARATION OF OPTICALLY ACTIVE 1,3-DIOXOLANE-4-METHANOL COMPOUNDS. AMERICAN HOSPITAL SUPPLY CORP (US) 1986-07-24 — — EP disclosed
EP-0173714-A1 PREPARATION OF OPTICALLY ACTIVE 1,3-DIOXOLANE-4-METHANOL COMPOUNDS. AMERICAN HOSPITAL SUPPLY CORP (US) 1986-03-12 — — EP disclosed
US-4575558-A Preparation of optically active 1,3-dioxolane-4-methanol compounds AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1986-03-11 — — US disclosed
WO-1985003704-A1 PREPARATION OF OPTICALLY ACTIVE 1,3-DIOXOLANE-4-METHANOL COMPOUNDS AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1985-08-29 — — WO disclosed
US-4127730-A Method of preparing polymers analogous to enzymes DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1978-11-28 — — US disclosed
US-4111863-A NON-SWELLABLE, THREE DIMENSIONAL DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1978-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182463-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG PREP, UNG, DPP4 L3MBTL1 2179/4885CA2 1644/4885HCRTR2 4703/4885
US-20250084099-A1 THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS MALT1, PTP4A1, AMY1A L3MBTL1 1314/4885CA2 1918/4885HCRTR2 4773/4885
US-11993613-B2 Thiazolo[5,4-b]pyridine MALT-1 inhibitors MALT1, PTP4A1, AMY1A L3MBTL1 1314/4885CA2 1918/4885HCRTR2 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.